A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life

A novel recombinant human growth hormone (rhGH) fusion protein (VRS-317) was designed to minimize receptor-mediated clearance through a reduction in receptor binding without mutations to rhGH by genetically fusing with XTEN amino acid sequences to the N-terminus and the C-terminus of the native hGH...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cleland, Jeffrey L, Geething, Nathan C, Moore, Jerome A, Rogers, Brian C, Spink, Benjamin J, Wang, Chai-Wei, Alters, Susan E, Stemmer, Willem P C, Schellenberger, Volker
פורמט: Artigo
שפה:Inglês
יצא לאור: Wiley Subscription Services, Inc., A Wiley Company 2012
נושאים:
Biotechnology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3427893/
https://ncbi.nlm.nih.gov/pubmed/22678811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jps.23229
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים